Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA388966 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR5638580_1.fastq.gz | Fastqsanger.gz | |||
| SRR5638580_2.fastq.gz | Fastqsanger.gz | |||
| SRR5638581_1.fastq.gz | Fastqsanger.gz | |||
| SRR5638581_2.fastq.gz | Fastqsanger.gz | |||
| SRR5638582_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 24 |
Similar Datasets
Project description:The obejctive of this study is to establish the therapeutic role of 6-thio-dG for gliomas in vitro and in vivo and to elucidate the anti-tumor mechanisms of 6-thio-dG in glioma cells. And the ultimate goal of this proposal is to demonstrate the potential of 6-thio-dG as a novel strategy for primary and recurrent glioma.
2021-09-13 | GSE180874 | GEO
Project description:The obejctive of this study is to establish the therapeutic role of 6-thio-dG for gliomas in vitro and in vivo and to elucidate the anti-tumor mechanisms of 6-thio-dG in glioma cells. And the ultimate goal of this proposal is to demonstrate the potential of 6-thio-dG as a novel strategy for primary and recurrent glioma.
2021-09-13 | GSE160619 | GEO
Project description:The evolution of drug-tolerant persister (DTP) cells into resistant clones remains a major obstacle to targeted therapies. Transcriptomic profiling across melanoma (A375, SK-MEL-28), non-small cell lung cancer (NSCLC; HCC827, PC-9), and colorectal cancer (CRC; SW480) models revealed a conserved biphasic telomerase regulation during DTP evolution. Combining targeted therapies with the telomere-dysfunction agent 6-thio-dG effectively suppressed DTP outgrowth and resistance in vitro and in vivo. Mechanistically, 6-thio-dG induces chromatin remodeling, reducing SUCLG2 locus accessibility and downregulating this mitochondrial enzyme to disrupt DTP metabolic stability. Consistently, SUCLG2 knockdown recapitulated these therapeutic effects. Furthermore, in vivo RNAseq of HCC827 xenografts confirmed the combination coordinately suppresses mitochondrial metabolism, telomere maintenance, and persister programs. Collectively, preemptively combining 6-thio-dG with targeted therapies is a potent strategy to disrupt DTP evolution and overcome adaptive resistance across diverse malignancies.
2026-05-21 | GSE329254 | GEO
Project description:The evolution of drug-tolerant persister (DTP) cells into resistant clones remains a major obstacle to targeted therapies. Transcriptomic profiling across melanoma (A375, SK-MEL-28), non-small cell lung cancer (NSCLC; HCC827, PC-9), and colorectal cancer (CRC; SW480) models revealed a conserved biphasic telomerase regulation during DTP evolution. Combining targeted therapies with the telomere-dysfunction agent 6-thio-dG effectively suppressed DTP outgrowth and resistance in vitro and in vivo. Mechanistically, 6-thio-dG induces chromatin remodeling, reducing SUCLG2 locus accessibility and downregulating this mitochondrial enzyme to disrupt DTP metabolic stability. Consistently, SUCLG2 knockdown recapitulated these therapeutic effects. Furthermore, in vivo RNAseq of HCC827 xenografts confirmed the combination coordinately suppresses mitochondrial metabolism, telomere maintenance, and persister programs. Collectively, preemptively combining 6-thio-dG with targeted therapies is a potent strategy to disrupt DTP evolution and overcome adaptive resistance across diverse malignancies.
2026-05-21 | GSE331127 | GEO
Project description:Telomerase promoter mutations are highly prevalent in human tumors including melanoma. Telomere transcriptional signatures are enriched in a subset of therapy-naïve melanomas associated with worse overall survival, in BRAF-mutant intrinsically resistant melanoma cells that evade MAPK inhibitors (MAPKi), as well as in a subset of post-treatment tumor biopsies derived from patients who have disease progression on MAPKi or the immune checkpoint inhibitors, anti-CTLA-4 or anti-PD1. We demonstrate the efficacy of a telomerase-directed nucleoside, 6-thio-2'-deoxyguanosine (6-thio-dG) that results in telomere dysfunction and cell death in various models of therapy-resistant cells. Furthermore, 6-thio-dG significantly inhibits tumor growth of primary tumor biopsy cultures derived from patients who had disease progression on multiple therapies including anti-CTLA-4 or anti-PD1.
2017-06-02 | GSE99552 | GEO
Project description:Standard and targeted therapies almost universally fail due to tumor heterogeneity/plasticity leading to intrinsic or acquired drug resistance. We used the telomerase substrate precursor 6-thio-2’-deoxyguanosine (6-thio-dG) to target telomerase-expressing targeted therapy and platin-doublet chemotherapy resistant cells. We observed that erlotinib, paclitaxel/carboplatin and gemcitabine/cisplatin resistant cells are sensitive to 6-thio-dG in xenograft, syngeneic immunocompetent and genetically engineered mouse models. We also show sensitivity to 6-thio-dG on a large panel of non-small cell lung cancer cell lines (73 of 77). The 4 resistant NSCLC lines clustered together, providing a molecular signature for patients that may not respond to 6-thio-dG. We find SLC43A3 as a top candidate in this molecular signature. Thus, 6-thio-dG may prolong disease control of therapy-resistant lung cancer patients.
2018-01-30 | GSE109821 | GEO
Project description:The evolution of cancer cells from a drug-tolerant persister (DTP) state into stably resistant clones is a primary barrier to the long-term efficacy of targeted therapies. Through longitudinal transcriptomic profiling across melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer models, we uncover a conserved, biphasic regulation of telomerase as a fundamental driver of this process. Combining targeted therapies with telomerase inhibition (genetic or pharmacological) in melanoma and NSCLC models suppressed DTP cell formation and resistance progression in vitro and in vivo. Mechanistic dissection via RNA-seq revealed SUCLG2 as a critical downstream effector of the telomerase inhibitor 6-thio-dG; SUCLG2 knockdown phenocopied combinatorial efficacy. Complementary ATAC-seq demonstrated 6-thio-dG–induced chromatin remodelling at the SUCLG2 locus, reducing accessibility to downregulate expression and thereby impeding DTP proliferation and resistance evolution. Collectively, we establish preemptive telomerase inhibition as a vulnerability-directed strategy to ablate adaptive resistance across malignancies.
2026-05-21 | GSE308782 | GEO
Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs.
2010-09-25 | GSE24338 | GEO
Project description:We have sequenced miRNA libraries from human embryonic, neural and foetal mesenchymal stem cells. We report that the majority of miRNA genes encode mature isomers that vary in size by one or more bases at the 3’ and/or 5’ end of the miRNA. Northern blotting for individual miRNAs showed that the proportions of isomiRs expressed by a single miRNA gene often differ between cell and tissue types. IsomiRs were readily co-immunoprecipitated with Argonaute proteins in vivo and were active in luciferase assays, indicating that they are functional. Bioinformatics analysis predicts substantial differences in targeting between miRNAs with minor 5’ differences and in support of this we report that a 5’ isomiR-9-1 gained the ability to inhibit the expression of DNMT3B and NCAM2 but lost the ability to inhibit CDH1 in vitro. This result was confirmed by the use of isomiR-specific sponges. Our analysis of the miRGator database indicates that a small percentage of human miRNA genes express isomiRs as the dominant transcript in certain cell types and analysis of miRBase shows that 5’ isomiRs have replaced canonical miRNAs many times during evolution. This strongly indicates that isomiRs are of functional importance and have contributed to the evolution of miRNA genes
2014-08-06 | GSE58734 | GEO
Project description:Transcriptional profiling of human mesenchymal stem cells comparing normoxic MSCs cells with hypoxic MSCs cells. Hypoxia may inhibit senescence of MSCs during expansion. Goal was to determine the effects of hypoxia on global MSCs gene expression.
2011-02-19 | GSE20463 | GEO